TickerFacts.

Fennec Pharmaceuticals Inc. (FENC): Shareholders' Equity

Annual figures by period end, from SEC filings.

$35.47M
As of 2025-12-31
$42.44M
As of 2026-06-30
+4.1%
5-year compound annual growth
n/m
10-year compound annual growth
1997-06-23: -$37.0K1997-06-30: -$37.0K1998-06-30: -$435.0K1999-06-30: $242.0K2000-06-30: $47.0K2001-06-30: $9.79M2002-06-30: $6.07M2003-06-30: $698.0K2004-06-30: $20.45M2004-12-31: $16.65M2005-12-31: $11.08M2006-12-31: $1.27M2007-12-31: $14.15M2008-12-31: $3.05M2009-12-31: $406.0K2010-12-31: -$4.92M2011-12-31: -$119.0K2012-12-31: -$4.96M2013-12-31: -$1.46M2014-12-31: $613.0K2015-12-31: $548.0K2016-12-31: $3.57M2017-12-31: $26.76M2018-12-31: $21.31M2019-12-31: $11.88M2020-12-31: $29.07M2021-12-31: $15.77M2022-12-31: -$2.57M2023-09-30: $9.58M2023-12-31: -$11.62M2024-12-31: -$5.87M2025-12-31: $35.47M$35.47M
1997-06-23 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$35.47Mn/m2026-03-27, Balance as of period end
2024-12-31-$5.87Mn/m2026-03-27, Balance as of period end
2023-12-31-$11.62Mn/a2025-03-26, Balance as of period end
2023-09-30$9.58Mn/a2024-03-29, Balance as of period end
2022-12-31-$2.57Mn/m2024-03-29, Balance as of period end
2021-12-31$15.77M-45.7%2023-03-29, Balance as of period end
2020-12-31$29.07M+144.8%2022-02-28, Balance as of period end
2019-12-31$11.88M-44.3%2021-03-30, Balance as of period end
2018-12-31$21.31M-20.3%2020-02-14, Balance as of period end
2017-12-31$26.76M+649.5%2019-03-15, Balance as of period end
2016-12-31$3.57M+551.5%2018-03-28, Balance as of period end
2015-12-31$548.0K-10.6%2017-03-29, Balance as of period end
2014-12-31$613.0Kn/m2016-03-28, Balance as of period end
2013-12-31-$1.46Mn/m2015-03-31, Balance as of period end
2012-12-31-$4.96Mn/m2014-03-31, Balance as of period end
2011-12-31-$119.0Kn/m2014-03-31, Balance as of period end
2010-12-31-$4.92Mn/m2014-03-31, Balance as of period end
2009-12-31$406.0K-86.7%2014-03-31, Balance as of period end
2008-12-31$3.05M-78.4%2014-03-31, Balance as of period end
2007-12-31$14.15Mn/m2014-03-31, Balance as of period end
2006-12-31$1.27M-88.6%2014-03-31, Balance as of period end
2005-12-31$11.08M-33.5%2014-03-31, Balance as of period end
2004-12-31$16.65Mn/a2014-03-31, Balance as of period end
2004-06-30$20.45Mn/m2014-03-31, Balance as of period end
2003-06-30$698.0K-88.5%2014-03-31, Balance as of period end
2002-06-30$6.07M-38.0%2014-03-31, Balance as of period end
2001-06-30$9.79Mn/m2014-03-31, Balance as of period end
2000-06-30$47.0K-80.6%2014-03-31, Balance as of period end
1999-06-30$242.0Kn/m2014-03-31, Balance as of period end
1998-06-30-$435.0Kn/m2014-03-31, Balance as of period end
1997-06-30-$37.0Kn/a2014-03-31, Balance as of period end
1997-06-23-$37.0Kn/a2013-04-01, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Fennec Pharmaceuticals Inc. (FENC)2025-12-31$35.47Mn/m
Editas Medicine, Inc. (EDIT)2025-12-31$27.29M-79.7%
Voyager Therapeutics, Inc. (VYGR)2025-12-31$196.08M-34.6%
Sangamo Therapeutics, Inc (SGMOQ)2025-12-31-$14.27Mn/m
Kymera Therapeutics, Inc. (KYMR)2025-12-31$1.58B+89.0%
Protalix BioTherapeutics, Inc. (PLX)2025-12-31$48.23M+11.6%
Invivyd, Inc. (IVVD)2025-12-31$241.54M+257.6%
C4 Therapeutics, Inc. (CCCC)2025-12-31$256.59M+18.8%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$186.29M+741.1%

Compare FENC, EDIT, VYGR, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗